Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2016

01-04-2016 | Original Paper

Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer

Authors: Ahmad Aljada, Joseph Doria, Ayman M. Saleh, Shahad H. Al-Matar, Sarah AlGabbani, Heba Bani Shamsa, Ahmad Al-Bawab, Altayeb Abdalla Ahmed

Published in: Cellular Oncology | Issue 2/2016

Login to get access

Abstract

Background

Lamin A/C alternative splice variants (Lamin A, Lamin C, Lamin AΔ10 and Lamin AΔ50) have been implicated in cell cycle regulation, DNA replication, transcription regulation, cellular differentiation, apoptosis and aging. In addition, loss of Lamin A/C expression has been observed in several cancers, including breast cancer, and it has been found that Lamin A/C suppression may lead to cancer-like aberrations in nuclear morphology and aneuploidy. Based on these observations, we hypothesized that Lamin A/C transcript variant quantification might be employed for the diagnosis of breast cancer.

Methods

Newly designed TaqMan qRT-PCR assays for the analysis of Lamin A/C splice variants were validated and their use as biomarkers for the diagnosis of breast cancer was assessed using 16 normal breast tissues and 128 breast adenocarcinomas. In addition, the expression levels of the Lamin A/C transcript variants were measured in samples derived from seven other types of cancer.

Results

We found that the expression level of Lamin C was significantly increased in the breast tumors tested, whereas the expression levels of Lamin A and Lamin AΔ50 were significantly decreased. No significant change in Lamin AΔ10 expression was observed. Our data also indicated that the Lamin C : Lamin A mRNA ratio was increased in all clinical stages of breast cancer. Additionally, we observed increased Lamin C : Lamin A mRNA ratios in liver, lung and thyroid carcinomas and in colon, ovary and prostate adenocarcinomas.

Conclusions

From our data we conclude that the Lamin C : Lamin A mRNA ratio is increased in breast cancer and that this mRNA ratio may be of diagnostic use in all clinical stages of breast cancer and, possibly, also in liver, lung, thyroid, colon, ovary and prostate cancers.
Literature
1.
J.L. Broers, B.M. Machiels, G.J. van Eys, H.J. Kuijpers, E.M. Manders, R. van Driel, F.C. Ramaekers, Dynamics of the nuclear lamina as monitored by GFP-tagged A-type lamins. J. Cell Sci. 112(Pt 20), 3463–3475 (1999)PubMed
2.
A. Taddei, F. Hediger, F.R. Neumann, S.M. Gasser, The function of nuclear architecture: a genetic approach. Annu. Rev. Genet. 38, 305–345 (2004)CrossRefPubMed
3.
4.
H. Cao, R.A. Hegele, LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J. Hum. Genet. 48, 271–274 (2003)CrossRefPubMed
5.
A. De Sandre-Giovannoli, R. Bernard, P. Cau, C. Navarro, J. Amiel, I. Boccaccio, S. Lyonnet, C.L. Stewart, A. Munnich, M. Le Merrer, N. Levy, Lamin a truncation in Hutchinson-Gilford progeria. Science 300, 2055 (2003)CrossRefPubMed
6.
M. Eriksson, W.T. Brown, L.B. Gordon, M.W. Glynn, J. Singer, L. Scott, M.R. Erdos, C.M. Robbins, T.Y. Moses, P. Berglund, A. Dutra, E. Pak, S. Durkin, A.B. Csoka, M. Boehnke, T.W. Glover, F.S. Collins, Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293–298 (2003)CrossRefPubMed
7.
B.M. Machiels, A.H. Zorenc, J.M. Endert, H.J. Kuijpers, G.J. van Eys, F.C. Ramaekers, J.L. Broers, An alternative splicing product of the lamin A/C gene lacks exon 10. J. Biol. Chem. 271, 9249–9253 (1996)CrossRefPubMed
8.
L. Mounkes, S. Kozlov, B. Burke, C.L. Stewart, The laminopathies: nuclear structure meets disease. Curr. Opin. Genet. Dev. 13, 223–230 (2003)CrossRefPubMed
9.
A. Muchir, H.J. Worman, The nuclear envelope and human disease. Physiology (Bethesda) 19, 309–314 (2004)CrossRef
10.
D. McClintock, D. Ratner, M. Lokuge, D.M. Owens, L.B. Gordon, F.S. Collins, K. Djabali, The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One 2, e1269 (2007)CrossRefPubMedPubMedCentral
11.
B.C. Capell, F.S. Collins, Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 7, 940–952 (2006)CrossRefPubMed
12.
13.
C.D. Capo-chichi, K.Q. Cai, J. Smedberg, P. Ganjei-Azar, A.K. Godwin, X.X. Xu, Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin. J. Cancer 30, 415–425 (2011)CrossRefPubMedPubMedCentral
14.
B.M. Machiels, J.L. Broers, Y. Raymond, L. de Ley, H.J. Kuijpers, N.E. Caberg, F.C. Ramaekers, Abnormal A-type lamin organization in a human lung carcinoma cell line. Eur. J. Cell Biol. 67, 328–335 (1995)PubMed
15.
C.D. Capo-chichi, B. Aguida, N.W. Chabi, Q.K. Cai, G. Offrin, V.K. Agossou, A. Sanni, X.-X. Xu, Lamin A/C deficiency is an independent risk factor for cervical cancer. Cell. Oncol. (2015). doi:10.​1007/​s13402-015-0252-6
16.
B. Stadelmann, E. Khandjian, A. Hirt, A. Luthy, R. Weil, H.P. Wagner, Repression of nuclear lamin A and C gene expression in human acute lymphoblastic leukemia and non-Hodgkin’s lymphoma cells. Leuk. Res. 14, 815–821 (1990)CrossRefPubMed
17.
R. Agrelo, F. Setien, J. Espada, M.J. Artiga, M. Rodriguez, A. Perez-Rosado, A. Sanchez-Aguilera, M.F. Fraga, M.A. Piris, M. Esteller, Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J. Clin. Oncol. 23, 3940–3947 (2005)CrossRefPubMed
18.
J.D. Debes, T.J. Sebo, H.V. Heemers, B.R. Kipp, D.L. Haugen, C.M. Lohse, D.J. Tindall, p300 modulates nuclear morphology in prostate cancer. Cancer Res. 65, 708–712 (2005)CrossRefPubMed
19.
L. Kong, G. Schafer, H. Bu, Y. Zhang, H. Klocker, Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis 33, 751–759 (2012)CrossRefPubMed
20.
N.D. Willis, T.R. Cox, S.F. Rahman-Casans, K. Smits, S.A. Przyborski, P. van den Brandt, M. van Engeland, M. Weijenberg, R.G. Wilson, A. de Bruine, C.J. Hutchison, Lamin A/C is a risk biomarker in colorectal cancer. PLoS One 3, e2988 (2008)CrossRefPubMedPubMedCentral
21.
N.D. Willis, R.G. Wilson, C.J. Hutchison, Lamin A: a putative colonic epithelial stem cell biomarker which identifies colorectal tumours with a more aggressive phenotype. Biochem. Soc. Trans. 36, 1350–1353 (2008)CrossRefPubMed
22.
E.J. Belt, R.J. Fijneman, E.G. van den Berg, H. Bril, P.M. Delis-van Diemen, M. Tijssen, H.F. van Essen, E.S. de Lange-de Klerk, J.A. Belien, H.B. Stockmann, S. Meijer, G.A. Meijer, Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Eur. J. Cancer 47, 1837–1845 (2011)CrossRefPubMed
23.
P. Scaffidi, T. Misteli, Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11, 440–445 (2005)CrossRefPubMedPubMedCentral
24.
S. Rodriguez, F. Coppede, H. Sagelius, M. Eriksson, Increased expression of the Hutchinson-Gilford progeria syndrome truncated lamin A transcript during cell aging. Eur. J. Hum. Genet. 17, 928–937 (2009)CrossRefPubMedPubMedCentral
25.
J.I. Toth, S.H. Yang, X. Qiao, A.P. Beigneux, M.H. Gelb, C.L. Moulson, J.H. Miner, S.G. Young, L.G. Fong, Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. U. S. A. 102, 12873–12878 (2005)CrossRefPubMedPubMedCentral
26.
C.L. Moulson, L.G. Fong, J.M. Gardner, E.A. Farber, G. Go, A. Passariello, D.K. Grange, S.G. Young, J.H. Miner, Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum. Mutat. 28, 882–889 (2007)CrossRefPubMed
27.
28.
I.C. Lopez-Mejia, M. de Toledo, C. Chavey, L. Lapasset, P. Cavelier, C. Lopez-Herrera, K. Chebli, P. Fort, G. Beranger, L. Fajas, E.Z. Amri, F. Casas, J. Tazi, Antagonistic functions of LMNA isoforms in energy expenditure and lifespan. EMBO Rep. 15, 529–539 (2014)CrossRefPubMedPubMedCentral
29.
J.L. Broers, B.M. Machiels, H.J. Kuijpers, F. Smedts, R. van den Kieboom, Y. Raymond, F.C. Ramaekers, A- and B-type lamins are differentially expressed in normal human tissues. Histochem. Cell Biol. 107, 505–517 (1997)CrossRefPubMed
30.
M.A. Eckersley-Maslin, J.H. Bergmann, Z. Lazar, D.L. Spector, Lamin A/C is expressed in pluripotent mouse embryonic stem cells. Nucleus 4, 53–60 (2013)CrossRefPubMedPubMedCentral
31.
R.A. Rober, K. Weber, M. Osborn, Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 105, 365–378 (1989)PubMed
32.
J. Swift, I.L. Ivanovska, A. Buxboim, T. Harada, P.C. Dingal, J. Pinter, J.D. Pajerowski, K.R. Spinler, J.W. Shin, M. Tewari, F. Rehfeldt, D.W. Speicher, D.E. Discher, Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 341, 1240104 (2013)CrossRefPubMedPubMedCentral
33.
H.J. Jung, J.M. Lee, S.H. Yang, S.G. Young, L.G. Fong, Nuclear lamins in the brain - new insights into function and regulation. Mol. Neurobiol. 47, 290–301 (2013)CrossRefPubMedPubMedCentral
34.
T. Wakabayashi, T. Mori, Y. Hirahara, T. Koike, Y. Kubota, Y. Takamori, H. Yamada, Nuclear lamins are differentially expressed in retinal neurons of the adult rat retina. Histochem. Cell Biol. 136, 427–436 (2011)CrossRefPubMed
35.
C.J. Hutchison, H.J. Worman, A-type lamins: guardians of the soma? Nat. Cell Biol. 6, 1062–1067 (2004)CrossRefPubMed
36.
F. Lin, H.J. Worman, Expression of nuclear lamins in human tissues and cancer cell lines and transcription from the promoters of the lamin A/C and B1 genes. Exp. Cell Res. 236, 378–384 (1997)CrossRefPubMed
37.
A. Matsumoto, M. Hieda, Y. Yokoyama, Y. Nishioka, K. Yoshidome, M. Tsujimoto, N. Matsuura, Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Canc. Med. 4, 1547–1557 (2015)CrossRef
38.
U. Wazir, M.H. Ahmed, J.M. Bridger, A. Harvey, W.G. Jiang, A.K. Sharma, K. Mokbel, The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer. Cell. Mol. Biol. Lett. 18, 595–611 (2013)CrossRefPubMed
39.
W.S. Lee, J.J. Jung, H.C. Jeung, S.W. Noh, B.K. Oh, K.Y. Kim, T.S. Kim, H.C. Chung, J.K. Roh, S.Y. Rha, Methylation status of lamin A/C in gastric cancer cell lines. Hepatogastroenterology 59, 1313–1318 (2012)CrossRefPubMed
40.
D. Constantinescu, H.L. Gray, P.J. Sammak, G.P. Schatten, A.B. Csoka, Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. Stem Cells 24, 177–185 (2006)CrossRefPubMed
41.
D. Lourim, J.J. Lin, Expression of nuclear lamin A and muscle-specific proteins in differentiating muscle cells in ovo and in vitro. J. Cell Biol. 109, 495–504 (1989)CrossRefPubMed
42.
B. Liu, J. Wang, K.M. Chan, W.M. Tjia, W. Deng, X. Guan, J.D. Huang, K.M. Li, P.Y. Chau, D.J. Chen, D. Pei, A.M. Pendas, J. Cadinanos, C. Lopez-Otin, H.F. Tse, C. Hutchison, J. Chen, Y. Cao, K.S. Cheah, K. Tryggvason, Z. Zhou, Genomic instability in laminopathy-based premature aging. Nat. Med. 11, 780–785 (2005)CrossRefPubMed
43.
A. Peter, R. Stick, Evolution of the lamin protein family: what introns can tell. Nucleus 3, 44–59 (2012)CrossRefPubMed
44.
Y.S. Oh, D.G. Kim, G. Kim, E.C. Choi, B.K. Kennedy, Y. Suh, B.J. Park, S. Kim, Downregulation of lamin A by tumor suppressor AIMP3/p18 leads to a progeroid phenotype in mice. Aging Cell 9, 810–822 (2010)CrossRefPubMed
Metadata
Title
Altered Lamin A/C splice variant expression as a possible diagnostic marker in breast cancer
Authors
Ahmad Aljada
Joseph Doria
Ayman M. Saleh
Shahad H. Al-Matar
Sarah AlGabbani
Heba Bani Shamsa
Ahmad Al-Bawab
Altayeb Abdalla Ahmed
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2016
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0265-1

Other articles of this Issue 2/2016

Cellular Oncology 2/2016 Go to the issue

Original Paper

Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer

Original Paper

Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor

Original Paper

Down-regulation of osteopontin mediates a novel mechanism underlying the cytostatic activity of TGF-β

Original Paper

Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation

Review

PSA and beyond: alternative prostate cancer biomarkers

Original Paper

PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits